



The Reliable Resource for the Biomedical Community

February 2011

Featured Animal Models at CBI

VX2 Tumor in Rabbits

GLP Efficacy Studies

TR ras Mouse Carcinogenicity

Mouse Lymphoma Test

Laser-Induced Choroidal Neovascularization in Rabbits

Antibody-Induced Arthritis in Mice

Myasthenia Gravis in Rats

::::

For more information, contact Mike Zamora at mike_zamora@compbio.com

Quick Links

[Contact Us](#)

[Our Website](#)

[About CBI](#)

Join Our Mailing List!

Comparative Biosciences, Inc.
786 Lucerne Drive
Sunnyvale, CA 94085

Phone: 408.738.9260
Fax: 408.738.9278

Visit our Booth at the SOT (booth 312)!

CBI congratulates AREVA Med on its successful IND and entry into Phase I alpha radioimmunotherapy clinical trial with ²¹²Pb.

Is the Venture Funding Drought Finally Over?

It looks like the Venture Funding Drought in Silicon Valley may finally be over. The Venture Capital Quarterly Report (San Jose Mercury News, 20Feb2011) indicates that money is now liberally flowing into new companies and BioTech is leading the way (24% of venture funding) with software investing coming in second. Over \$2B was invested in the last quarter with a 19.8% increase from last year to \$21.8B in 2011. 40% of this venture money has flowed into Silicon Valley. Twitter was the biggest VC deal with \$200M in venture funding this year, but a new biopharmaceutical company, Pearl Therapeutics in Redwood City got a whopping \$38M in Venture Funding recently. There was also a decline in venture investment in medical device companies. It is clear that if our industry could increase the number of successful INDS and NDAs, more venture money would be flowing into our industry again.

First New Drug Approval for 2011!

FDA NEWS RELEASE

FDA approves product to prevent bleeding in people with rare genetic defect Corifact is 1st treatment for the rare congenital Factor XIII Deficiency. The number of NMEs approved for the past 5 years is presented (derived from the FDA website).

Calendar Year	NMEs Approved
2006	22
2007	18
2008	24
2009	26
2010	21

VX2 Tumor Model in Rabbits

The Shope papillomavirus provided the first mammalian model of a cancer caused by a virus (Wikipedia). It takes its name from Dr. Richard E. Shope, who discovered it in the 1930s. Dr. Shope was able to isolate virus particles from tumors on captured animals and use these to inoculate domestic rabbits, which then developed similar tumors. The virus was sequenced in 1984, showing substantial sequence similarities to HPV1a. It has been used as a model for human papillomaviruses both before and after this discovery. The most visible example of this role is the HPV vaccine, which was developed based on and incorporating research done using the virus as a model. Similarly, it has been used to investigate antiviral therapies. Currently, the tumor cell line is commonly used in rabbits to establish subcutaneous tumors, but there are also current references to the cell line being used intra-auricularly to establish head and neck carcinomas, and injected into the carotid to establish brain tumors, as well as other sites.

CBI has established the VX2 cell line in house and is now offering oncology studies in rabbits using the VX2 cell line.

For information on pre-clinical ophthalmic pharmacokinetics, efficacy modeling and toxicology services offered at CBI, contact Mike Zamora, Business Development Manager

Tel: 408-738-9265

Email: mike_zamora@compbio.com